Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

US Patent Granted for Verona Pharma’s RPL554

Published: Tuesday, January 01, 2013
Last Updated: Tuesday, January 01, 2013
Bookmark and Share
Company is currently carrying out clinical trials of the drug, RPL554.

Verona Pharma plc has announced that the United States Patent and Trademark Office has granted a new patent for the Company’s lead drug candidate, RPL554.

The patent is the fourth patent issued for RPL554 and related compounds in the US.

RPL554, Verona Pharma's lead drug candidate, is a dual phosphodiesterase 3 and 4 inhibitor with both bronchodilator and anti-inflammatory properties.

RPL554 is being developed for the treatment of patients with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.

The Company is currently carrying out clinical trials of the drug to further characterize its bronchodilator and anti-inflammatory effects.

Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: “We are growing the intellectual property portfolio around the RPL554 programme and the issue of this new US Patent strengthens and harmonizes our international patent estate around RPL554 and provides exclusivity in one of the world’s leading pharmaceutical markets. We continue to develop our intellectual property rights as this is a key part of Verona Pharma’s strategy.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Verona Pharma Reports Bronchodilator Data with RPL554 in COPD Patients
Data was presented at the 2012 European Respiratory Society Annual Congress in Vienna.
Tuesday, January 15, 2013
Verona Pharma Appoints Manchester Clinical Research Facility to Carry Out Clinical Trial with RPL554
Enrollment of patients to start Q2, with results expected early Q4 2012.
Friday, March 09, 2012
Verona Pharma Successfully Completes £3.25 Million Placing
Placing to provide Company with sufficient working capital to finance RPL554 clinical trial programme.
Monday, December 12, 2011
Verona Pharma Announces Positive Results for RPL554 in Mild Asthma at Higher Doses
Verona has completed a successful trial in which 20 mild asthmatic subjects treated with either single doses of RPL554 or placebo administered via a nebulizer.
Wednesday, February 23, 2011
Verona Pharma Applies for Approval to Test RPL554 in UK Clinical Trials
RPL554 is Verona Pharma’s lead drug compound which is a long acting bronchodilator/anti-inflammatory drug belonging to a class of drugs known as a mixed PDE 3/4 inhibitor.
Monday, February 14, 2011
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos